CERT Certara, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CERT matters now
Certara, Inc. (CERT) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.77 with -0.29% on the session and $1.05B in market capitalization; recent performance reads 1-month +20.70% and YTD -37.12%.
The latest financial table shown here is Q1 2026, with revenue of $106.9M, net income of $-8.8M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 10.3%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $9.00; recent insider activity includes Corcoran Daniel filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.86
P/S
2.05
EV/EBITDA
10.00
DCF Value
$6.17
FCF Yield
10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.1%
Operating Margin
4.1%
Net Margin
-3.6%
ROE
-1.4%
ROA
-1.0%
ROIC
1.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $106.9M | $-8.8M | $-0.06 |
| Q4 2025 | $103.6M | $-5.9M | $-0.04 |
| FY 2025 | $418.8M | $-1.6M | $-0.01 |
| Q3 2025 | $104.6M | $1.5M | $0.01 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$8.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.49
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.